Dr. James Melotek on Cetuximab/Chemotherapy Combinations in Head and Neck Cancer

James Melotek, MD

Melotek says the trial's primary endpoint was comparison of efficacy when cetuximab is added to both therapies with historical control, with a secondary endpoint being further investigation of the usefulness of both chemotherapy platforms.

James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses the analysis of a recent phase II randomized trial looking into the combination of cetuximab with induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.

Melotek says the trial's primary endpoint was comparison of efficacy when cetuximab is added to both therapies with historical control, with a secondary endpoint being further investigation of the usefulness of both chemotherapy platforms. Those platforms are cetuximab 5-FU, and hydroxyurea with concomitant radiotherapy twice daily versus cetuximab, cisplatin and accelerated radiotherapy with delayed concomitant boost.